Advertisement

Covidien CFO Charles Dockendorff says there's not much room for growth in biologic tissue mesh for hernia repair, a product the company acquired in 2008.

Covidien logo

Covidien's (NYSE:COV) biologic hernia mesh product has hit a "brick wall," according to CFO Charles Dockendorff, but does that mean the company is looking to move on from the product it dropped more than $80 million to acquire?

Dockendorff, responding to a question from CitiGroup analyst Matthew Dodds at the investment bank's recent investor's conference, sounded downbeat about the fate of the product compared to the company's synthetic mesh.

Advertisement
Advertisement